Adcock Ingram Holdings Ltd
JSE:AIP
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| ZA |
A
|
Adcock Ingram Holdings Ltd
JSE:AIP
|
12.1B ZAR |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
987.9B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
596.5B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
293B CHF |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
249.7B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
240.5B GBP |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
307.4B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
156.9B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
125.6B USD |
Loading...
|
Market Distribution
| Min | -0.2% |
| 30th Percentile | 34.5% |
| Median | 45.2% |
| 70th Percentile | 46.1% |
| Max | 1 556.3% |
Other Profitability Ratios
Adcock Ingram Holdings Ltd
Glance View
Nestled in the competitive landscape of the pharmaceutical industry, Adcock Ingram Holdings Ltd. stands as a testament to resilience and evolution. Originating in South Africa, the company has built a legacy that combines a strong local presence with strategic global aspirations. Adcock Ingram’s journey is marked by an adaptive approach that blends innovation with consumer health needs. Its primary revenue streams flow from the development, manufacturing, and distribution of a wide array of healthcare products, including prescription medicines, over-the-counter formulations, and hospital medications. By maintaining a robust supply chain and nurturing partnerships both locally and internationally, the company ensures the steady availability of essential healthcare products across markets. The company’s recipe for success is enriched by a deep-rooted commitment to quality and research-driven practices. By investing in cutting-edge manufacturing facilities and a well-structured distribution network, Adcock Ingram manages to sustain efficiency and scale. This approach does not merely hinge on the core pharmaceutical business but extends to leveraging diverse consumer brands across various segments such as personal care and nutritional products. Their diverse portfolio not only mitigates risks associated with the volatile pharmaceutical industry but also aligns with the ever-evolving consumer health trends. In essence, Adcock Ingram thrives by intertwining strategic foresight with robust operational excellence, steadfastly serving the health and well-being of its customers.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Adcock Ingram Holdings Ltd is 27.9%, which is below its 3-year median of 30.6%.
Over the last 3 years, Adcock Ingram Holdings Ltd’s Gross Margin has decreased from 29.8% to 27.9%. During this period, it reached a low of 27.9% on Jun 30, 2025 and a high of 35.2% on Dec 31, 2022.